Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells

Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, 3, 991, 10.1038/ni1102-991 Ostrand-Rosenberg, 2004, Animal models of tumor immunity, immunotherapy and cancer vaccines, Curr Opin Immunol, 16, 143, 10.1016/j.coi.2004.01.003 Marsman, 2005, Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis, Adv Cancer Res, 93, 129, 10.1016/S0065-230X(05)93004-2 Moretta, 2005, Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis, Immunol Lett, 100, 7, 10.1016/j.imlet.2005.07.004 Srivastava, 2013, Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients, Clin Cancer Res, 19, 1858, 10.1158/1078-0432.CCR-12-2426 Campoli, 2004, HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications, Breast Dis, 20, 105, 10.3233/BD-2004-20112 Campoli, 2005, Mechanisms of tumor evasion, Cancer Treat Res, 123, 61, 10.1007/0-387-27545-2_3 Marincola, 2003, Tumors as elusive targets of T-cell-based active immunotherapy, Trends Immunol, 24, 335, 10.1016/S1471-4906(03)00116-9 Seliger, 2002, HLA class I antigen abnormalities and immune escape by malignant cells, Semin Cancer Biol, 12, 3, 10.1006/scbi.2001.0404 Whiteside, 2006, Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention, Semin Cancer Biol, 16, 3, 10.1016/j.semcancer.2005.07.008 Meissner, 2005, Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome, Clin Cancer Res, 11, 2552, 10.1158/1078-0432.CCR-04-2146 Ciechanover, 2012, Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting, Biochim Biophys Acta, 1824, 3, 10.1016/j.bbapap.2011.03.007 Watts, 2012, The endosome-lysosome pathway and information generation in the immune system, Biochim Biophys Acta, 1824, 14, 10.1016/j.bbapap.2011.07.006 Yewdell, 2001, Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing, Trends Cell Biol, 11, 294, 10.1016/S0962-8924(01)02030-X Joffre, 2012, Cross-presentation by dendritic cells, Nat Rev Immunol, 12, 557, 10.1038/nri3254 Koegl, 1999, A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly, Cell, 96, 635, 10.1016/S0092-8674(00)80574-7 Aki, 1994, Interferon-gamma induces different subunit organizations and functional diversity of proteasomes, J Biochem, 115, 257, 10.1093/oxfordjournals.jbchem.a124327 Shin, 2006, Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection, J Clin Invest, 116, 3006, 10.1172/JCI29832 Gaczynska, 1994, Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7, Proc Natl Acad Sci USA, 91, 9213, 10.1073/pnas.91.20.9213 Toes, 2001, Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products, J Exp Med, 194, 1, 10.1084/jem.194.1.1 Arora, 2001, Use of chimeric proteins to investigate the role of transporter associated with antigen processing (TAP) structural domains in peptide binding and translocation, Proc Natl Acad Sci USA, 98, 7241, 10.1073/pnas.131132198 Higgins, 2004, The ATP switch model for ABC transporters, Nat Struct Mol Biol, 11, 918, 10.1038/nsmb836 Parcej, 2010, ABC proteins in antigen translocation and viral inhibition, Nat Chem Biol, 6, 572, 10.1038/nchembio.410 Ortmann, 1994, MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding, Nature, 368, 864, 10.1038/368864a0 Grandea, 1997, Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin, Immunogenetics, 46, 477, 10.1007/s002510050308 Hatomoto, 1984, Patients with limited life possibilities (1): support of cancer patients. Interactions with patients who suspected cancer, Kurinikaru Sutadi, 5, 103 Lehner, 1998, Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220, Immunity, 8, 221, 10.1016/S1074-7613(00)80474-4 Sant, 2003, Antigen processing and recognition, Curr Opin Immunol, 15, 66, 10.1016/S0952-7915(02)00020-1 Ogino, 2006, HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker, Cancer Res, 66, 9281, 10.1158/0008-5472.CAN-06-0488 Liu, 2009, Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression, Scand J Gastroenterol, 44, 960, 10.1080/00365520902998679 Qifeng, 2011, Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics, J Thorac Cardiovasc Surg, 141, 808, 10.1016/j.jtcvs.2010.04.031 Ayshamgul, 2011, Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer, Chin Med J (Engl), 124, 341 Hirata, 2007, Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability, J Pathol, 211, 516, 10.1002/path.2142 Kloor, 2005, Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers, Cancer Res, 65, 6418, 10.1158/0008-5472.CAN-05-0044 Atkins, 2004, MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma, Int J Cancer, 109, 265, 10.1002/ijc.11681 Dierssen, 2007, HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression, BMC Cancer, 7, 33, 10.1186/1471-2407-7-33 Romero, 2005, Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer, Int J Cancer, 113, 605, 10.1002/ijc.20499 Cathro, 2010, Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas, Cancer Immunol Immunother, 59, 465, 10.1007/s00262-009-0765-9 Seliger, 2010, Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer, Cancer Immunol Immunother, 59, 529, 10.1007/s00262-009-0769-5 Kageshita, 1999, Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression, Am J Pathol, 154, 745, 10.1016/S0002-9440(10)65321-7 Kamarashev, 2001, TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis, Int J Cancer, 95, 23, 10.1002/1097-0215(20010120)95:1<23::AID-IJC1004>3.0.CO;2-4 Hasim, 2012, Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women, PLoS ONE, 7, e44952, 10.1371/journal.pone.0044952 Dovhey, 2000, Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line, Cancer Res, 60, 5789 Respa, 2011, Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines, Clin Cancer Res, 17, 2668, 10.1158/1078-0432.CCR-10-2114 Bandoh, 2010, HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis, Oncol Rep, 23, 933, 10.3892/or_00000717 Feenstra, 1999, HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas, Tissue Antigens, 54, 235, 10.1034/j.1399-0039.1999.540304.x Lopez-Albaitero, 2006, Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL, J Immunol, 176, 3402, 10.4049/jimmunol.176.6.3402 Pandha, 2007, Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines, Clin Exp Immunol, 148, 127, 10.1111/j.1365-2249.2006.03289.x Dissemond, 2003, Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression, Melanoma Res, 13, 253, 10.1097/00008390-200306000-00005 Seliger, 2001, Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway, Cancer Res, 61, 8647 Yang, 2003, A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line, J Biol Chem, 278, 15291, 10.1074/jbc.M300954200 Ayalon, 1998, Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis, Proc Natl Acad Sci USA, 95, 2435, 10.1073/pnas.95.5.2435 Ma, 1997, Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells, J Biol Chem, 272, 16585, 10.1074/jbc.272.26.16585 Ferris, 2006, Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer, Clin Cancer Res, 12, 3890, 10.1158/1078-0432.CCR-05-2750 Mehta, 2007, Genetic variation of antigen processing machinery components and association with cervical carcinoma, Genes Chromosom Cancer, 46, 577, 10.1002/gcc.20441 Fowler, 2004, Mutations in TAP genes are common in cervical carcinomas, Gynecol Oncol, 92, 914, 10.1016/j.ygyno.2003.11.037 Chen, 1996, A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer, Nat Genet, 13, 210, 10.1038/ng0696-210 Ogino, 2003, Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients, Clin Cancer Res, 9, 4043 Liu, 2012, Expression of antigen processing and presenting molecules in brain metastasis of breast cancer, Cancer Immunol Immunother, 61, 789, 10.1007/s00262-011-1137-9 Chang, 2015, Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy, J Biol Chem, 290, 26562, 10.1074/jbc.M115.676130 Tang, 2009, Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines, Arch Med Res, 40, 256, 10.1016/j.arcmed.2009.04.004 Yamamoto, 1999, Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features, Gastroenterology, 116, 1348, 10.1016/S0016-5085(99)70499-3 de Miranda, 2009, MUTYH-associated polyposis carcinomas frequently lose HLA class I expression – a common event amongst DNA-repair-deficient colorectal cancers, J Pathol, 219, 69, 10.1002/path.2569 Bicknell, 1996, Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas, Curr Biol, 6, 1695, 10.1016/S0960-9822(02)70795-1 Cabrera, 1998, High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas, Tissue Antigens, 52, 114, 10.1111/j.1399-0039.1998.tb02274.x Cabrera, 2007, Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms, Tissue Antigens, 69, 264, 10.1111/j.1399-0039.2006.00777.x White, 1998, Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells, Int J Cancer, 75, 590, 10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D Maleno, 2002, Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21, Cancer Immunol Immunother, 51, 389, 10.1007/s00262-002-0296-0 Cabrera, 2000, High frequency of altered HLA class I phenotypes in laryngeal carcinomas, Hum Immunol, 61, 499, 10.1016/S0198-8859(00)00097-5 Seliger, 2008, Molecular mechanisms of MHC class I abnormalities and APM components in human tumors, Cancer Immunol Immunother, 57, 1719, 10.1007/s00262-008-0515-4 Cancer Genome Atlas Research N, 2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038/nature11404 Cancer Genome Atlas N, 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129 Han, 2008, HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma, Clin Cancer Res, 14, 3372, 10.1158/1078-0432.CCR-07-4433 Racanelli, 2010, Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma, Blood, 115, 1185, 10.1182/blood-2009-06-228676 Leone, 2013, MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells, J Natl Cancer Inst, 105, 1172, 10.1093/jnci/djt184 Concha-Benavente, 2013, EGFR-mediated tumor immunoescape: the imbalance between phosphorylated STAT1 and phosphorylated STAT3, Oncoimmunology, 2, e27215, 10.4161/onci.27215 Leibowitz, 2013, SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells, Clin Cancer Res, 19, 798, 10.1158/1078-0432.CCR-12-1517 Agazie, 2003, Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling, Mol Cell Biol, 23, 7875, 10.1128/MCB.23.21.7875-7886.2003 Ferris, 2005, Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance, Immunol Res, 33, 113, 10.1385/IR:33:2:113 Chang, 2005, Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions, Adv Cancer Res, 93, 189, 10.1016/S0065-230X(05)93006-6 Srivastava, 2015, STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients, Cancer Immunol Res, 3, 936, 10.1158/2326-6066.CIR-15-0053 Concha-Benavente, 2015, Identification of the cell-intrinsic and extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer, Cancer Res Blattman, 2004, Cancer immunotherapy: a treatment for the masses, Science, 305, 200, 10.1126/science.1100369 Rosenberg, 2004, Development of effective immunotherapy for the treatment of patients with cancer, J Am Coll Surg, 198, 685, 10.1016/j.jamcollsurg.2004.01.025